SCHEMBL4134176

SCHEMBL4134176

CC(=C1SC(Nc2ccc(C(Br)C(=O)O)c(F)c2)=NC1=O)c1ccc([N+](=O)[O-])cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 1/20 0.36
AKR1C2 P52895 1/20 0.36
MAPT P10636 8/20 0.34
MEN1 O00255 5/20 0.34
KMT2A Q03164 5/20 0.34
MAPK1 P28482 3/20 0.34
NPC1 O15118 3/20 0.34
LMNA P02545 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
MITF O75030 1/20 0.34
POLB P06746 1/20 0.34
RAB9A P51151 3/20 0.33
KDM4E B2RXH2 1/20 0.32
KDM6B O15054 1/20 0.32
FTO Q9C0B1 1/20 0.32
EGLN1 Q9GZT9 1/20 0.32
HIF1AN Q9NWT6 1/20 0.32
KDM5B Q9UGL1 1/20 0.32
ABCB1 P08183 1/20 0.32
ABCC1 P33527 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4134174 1.00 AKR1C3 (0.36) AKR1C3AKR1C2MAPTMEN1KMT2A
SCHEMBL4634491 0.80 P2RX3 (0.33) MAPTMAPK1POLBKDM6BFTO
SCHEMBL4122732 0.73 PTGS1 (0.38) AKR1C3AKR1C2MAPTMEN1KMT2A
SCHEMBL4634547 0.73 PTGS1 (0.38) AKR1C3AKR1C2MAPTMEN1KMT2A
SCHEMBL4133272 0.72 MEN1 (0.41) MAPTMEN1KMT2AMAPK1LMNA
SCHEMBL4133274 0.72 MEN1 (0.41) MAPTMEN1KMT2AMAPK1LMNA
SCHEMBL4137074 0.66 ALOX5 (0.36) MAPTPOLB
SCHEMBL4128816 0.65 KMT2A (0.47) MAPTMEN1KMT2ALMNAPOLB
SCHEMBL20764585 0.61 HPGD (0.59) AKR1C3AKR1C2MAPTMEN1KMT2A
SCHEMBL5465076 0.59 TDP1 (0.78) AKR1C3AKR1C2MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US claimed
CN-101268060-A Thiazolinone and oxazolinone compounds and application thereof as PTP1B inhibitor TORRENT PHARMACEUTICALS LTD (IN) 2008-09-17 CN claimed
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US disclosed
CN-101268060-A Thiazolinone and oxazolinone compounds and application thereof as PTP1B inhibitor TORRENT PHARMACEUTICALS LTD (IN) 2008-09-17 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors PTPRF, PTPA, PTPRJ AKR1C3 2564/4885AKR1C2 1688/4885MAPT 3532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.